Table 1

Significant changes in predicted drug-resistance-related orthologs using KEGG after anti-Helicobacter pylori treatment in stool samples

Drug-resistance-related orthologsAlteration trend after treatmentMean relative frequency before treatmentMean relative frequency after treatmentFold change* Q value†
Successful eradication group
 K08164 MFS transporter, DHA1 family, chloramphenicol-resistance protein4.85E-071.11E-062.280.024
 K08221 MFS transporter, aromatic compound/drug exporter family, multidrug-resistance protein4.79E-071.08E-062.260.026
 K03327 multidrug-resistance protein, multidrug and toxin extrusion family9.64E-048.26E-040.860.011
 K03543 multidrug-resistance protein A2.06E-041.57E-040.760.008
 K08169 MFS transporter, DHA2 family, multidrug-resistance protein1.76E-041.30E-040.740.024
 K08223 MFS transporter, fosmidomycin resistance family, fosmidomycin-resistance protein2.53E-041.84E-040.730.007
Failed treatment group
 K08164 MFS transporter, DHA1 family, chloramphenicol-resistance protein4.27E-071.21E-062.820.005
 K08221 MFS transporter, aromatic compound/drug exporter family, multidrug-resistance protein4.01E-071.17E-062.920.005
 K02546 methicillin-resistance regulatory protein1.12E-084.10E-083.640.007
 K07681 two-component system, NarL family, vancomycin-resistance sensor histidine kinase VraS(EC:2.7.13.3)7.10E-072.56E-063.610.007
 K08151 MFS transporter, DHA1 family, tetracycline-resistance protein2.00E-066.58E-063.290.009
 K08152 MFS transporter, DHA1 family, multidrug-resistance protein B9.71E-061.44E-051.480.025
 K08153 MFS transporter, DHA1 family, multidrug-resistance protein3.52E-067.81E-062.220.009
 K08161 MFS transporter, DHA1 family, multidrug-resistance protein3.01E-055.75E-051.910.017
 K08170 MFS transporter, DHA2 family, multidrug-resistance protein3.97E-061.29E-053.250.007
 K11814 multidrug-resistance protein EbrA1.70E-091.90E-0810.610.005
 K11815 multidrug-resistance protein EbrB6.52E-092.77E-084.210.020
  • *The fold change was calculated as the ratio of the mean relative frequency after treatment to the mean relative frequency before treatment.

  • †Paired t-test after arcsine transformation of relative frequency and q values were used after adjustment for multiple comparison by the FDR.

  • DHA, drug:H+ antiporter; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; MFS, major facilitator superfamily.